Nuala Helsby (FBPhS) is a Professor in Pathology at the University of Auckland. Her research focus is on understanding how both inherited and environmental factors influence the safe and effective use of drugs. Nuala has more than 35 years of experience in the field of drug metabolism and pharmacogenetics (orcid.org/0000-0001-6570-5368). She has a particular interest in the factors which result in discordance between genotype and phenotype. Her research also focusses on understanding the role of inter-individual variation in the formation of toxic metabolites to improve the safety of drugs in current clinical use. She teaches extensively in the Biomedical Science and Pharmacology programmes and also serves on a number of NZ-based grant assessment panels.

Dr. Stephen P Ackland is a senior academic medical oncologist and Professor in the School of Medicine and Public Health, University of Newcastle Australia; Editor-in-Chief, Asia Pacific Journal of Clinical Oncology since 2005; and Director, Australasian GastroIntestinal Trials Group. He is author of >160 peer-reviewed publications in oncology and pharmacology, with a H-index of 39, in subjects ranging from pre-clinical pharmacology and pharmacogenomics to clinical trials and implementation science. He has previously been Director of Medical Oncology at Calvary Mater Newcastle Hospital; Director of Hunter Cancer Research Alliance; Director and Chairman of ANZ Breast Cancer Trials Group; and Director of Cancer Council NSW. He has participated in many committees of NFP cancer organisations in Australia and elsewhere, including MOGA, COSA, ASCO, Cancer Council, and NSW Office of Health and Medical Research. As EIC of APJCO he has led a team of 20-30 voluntary Associate Editors in evaluation and acceptance of manuscripts in clinical and translational oncology. This task has become an increasing challenge in this technological and pandemic age. http://www.newcastle.edu.au/profile/stephen-ackland